about
Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatmentEarly activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injuryTumor necrosis factor-alpha stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: down-regulation by cAMPAntibiotics induce apoptosis of human peritoneal mesothelial cells.Bradykinin enhances reactive oxygen species generation, mitochondrial injury, and cell death induced by ATP depletion--a role of the phospholipase C-Ca(2+) pathway.Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis.Nasal carriage of methicillin-resistant Staphylococcus aureus is associated with higher all-cause mortality in hemodialysis patients.Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury.Cysteine-rich protein 61 plays a proinflammatory role in obstructive kidney fibrosis.Cardiopulmonary resuscitation in dialysis patients.Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.Angiopoietins modulate endothelial adaptation, glomerular and podocyte hypertrophy after uninephrectomy.Safety issues of long-term glucose load in patients on peritoneal dialysis--a 7-year cohort study.Pentoxifylline: a potential therapy for chronic kidney disease.The renoprotective potential of pentoxifylline in chronic kidney disease.Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis.Continuous ambulatory peritoneal dialysis in the elderly: a seven-year experienceLifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan.Associations of metabolic syndrome and its components with cardiovascular outcomes among non-diabetic patients undergoing maintenance peritoneal dialysis.Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor.Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients.Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.Viral hepatitis infection should be considered for evaluating uremic pruritus in continuous ambulatory peritoneal dialysis patients.GB virus C/hepatitis G virus infection in patients on continuous ambulatory peritoneal dialysis.Risk factors for high dialysate glucose use in PD patients--a retrospective 5-year cohort study.Maintenance haemodialysis and delayed administration of appropriate antibiotics increase 30-day mortality among patients with non-hospital-acquired meticillin-resistant Staphylococcus aureus bacteraemia.Correlations between spiritual beliefs and health-related quality of life of chronic hemodialysis patients in Taiwan.Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation.Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells.Chronic fatigue in long-term peritoneal dialysis patients.Women on hemodialysis have lower self-reported health-related quality of life scores but better survival than men.The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patients.Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis.Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation.Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis.Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition.Health-related quality of life of hemodialysis patients in Taiwan: a multicenter study.Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients.Plasma interleukin-18 levels in chronic renal failure and continuous ambulatory peritoneal dialysis.
P50
Q27005803-60C38BE8-1786-466F-89D7-6AC1B67C55FFQ28570140-A449EA7F-B842-4C8A-98E0-B0FE6E02E1A1Q28574982-4DE62B1D-7FAA-4B95-B751-FE7F0DC8A467Q33199248-73F56B9B-1D83-48AE-8675-2D2C3278A307Q33292533-6B8F1E52-B0E6-4018-82CF-8EFA6E249B10Q34202707-6499DD39-3F7D-4F9F-B38C-62D43D745C37Q34497215-29F05508-2718-4D7B-908A-51FFC19C0609Q34568791-75CCB2C8-2BBA-4202-9CDC-9B21277EAC81Q34606850-5F9E6B63-7816-4F63-8039-8C8F1DF6BDB6Q34620525-810018A9-2260-4060-904E-DB6600918999Q35045007-4D67DF14-8F25-455C-AE1F-8D110B9EF6B6Q35075339-4FFB8FD1-B219-41F3-95EA-9419B31FFDAAQ35690340-7B18922C-9A75-4756-94A6-C59FF1BA1CD6Q35885208-AABD62FC-D5CF-48C8-ACD5-919345DF5276Q36090473-35A3FD16-1F7B-4871-B7E2-7761B9EBC02DQ36511515-7B2D4DA2-83E7-4CCC-B7A4-F1143AC383A4Q36680156-8F8DADAD-EDA0-4B16-ADF7-A1E9DA77E750Q37389816-68A55DC5-986E-41CD-8CCE-963452BC4644Q37874849-92549278-F5DB-4B43-8A61-553B51DFDC26Q40403528-880C1153-B1DA-47EB-BA60-66714229122CQ40485927-A028B4B4-5359-4DE2-B2DF-51B0354CE744Q42492171-DA50C825-D769-4F10-B774-342D59BC0EB3Q42878128-BA5C39EA-6694-40E9-B45B-7CB269BD69F3Q42989257-755D3C7A-2588-479F-8576-882052D0CECDQ42991020-62E37A3D-30C4-4793-BBF0-C60DF0E5944FQ43130276-4B7FE7E5-0529-4719-A571-79D13BA29172Q43631431-20CF516C-548A-467F-A981-98453BCD03B0Q43691859-8F0967EC-99CA-4234-BFEF-E43E3284E1BFQ43725706-758E4171-46AA-4333-8090-2965DC105913Q43750320-BA740084-480F-4190-AA7E-3D8DD76F74E3Q43859380-256FA8D2-DC03-411D-8794-E6E12D17A6B2Q44045592-6D119BBA-45EB-4187-9149-3122E69FC418Q44187134-665F3400-2325-452F-A19B-60FEB98F1184Q44362306-A71BE1F8-5316-4C8C-ACF6-798BC1567FC5Q44590860-1E1B38AB-695A-4B57-BEEC-876C07280A98Q44648235-2BB72156-954A-42C0-8DA6-F02AFBCB0DADQ44772848-CAC4C0AA-8F8E-43E2-9DDB-8AFC28543E40Q45137187-C8CC39E2-9B62-41AA-BC89-8175A0B204BFQ45234799-3C56F8B9-BA3C-4123-A8B2-D710075EADF0Q45242409-5F51E87A-92AA-45D9-8A25-A3D32969C413
P50
description
researcher ORCID ID = 0000-0002-1666-8940
@en
wetenschapper
@nl
name
Tun-Jun Tsai
@ast
Tun-Jun Tsai
@en
Tun-Jun Tsai
@es
Tun-Jun Tsai
@nl
type
label
Tun-Jun Tsai
@ast
Tun-Jun Tsai
@en
Tun-Jun Tsai
@es
Tun-Jun Tsai
@nl
prefLabel
Tun-Jun Tsai
@ast
Tun-Jun Tsai
@en
Tun-Jun Tsai
@es
Tun-Jun Tsai
@nl
P1153
7401925709
P31
P496
0000-0002-1666-8940